PD 0325901, also known as mirdametinib, is a potent, selective, and orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). As a second-generation MEK… Read more
PD 0325901, also known as mirdametinib, is a potent, selective, and orally bioavailable small-molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK1/2). As a second-generation MEK inhibitor, it functions by binding to an allosteric site to block the RAS-RAF-MEK-ERK signaling pathway, which is critical for cell proliferation and survival. This therapeutic agent is indicated for the treatment of adult and pediatric patients with symptomatic, inoperable neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas. Analytical laboratories utilize high-quality reference standards, metabolites, and stable isotope-labelled compounds related to PD 0325901 for rigorous impurity profiling, method validation, and quality control. These essential analytical tools support precise quantification and characterization of the drug substance, ensuring reliable results during development and clinical research of this targeted therapy.